Sequent Medical, a Aliso Viejo, California-based medical-device company, closed a $20.0m Series D venture capital financing.
The round was led by existing investor Delphi Ventures with participation from existing investors Domain Associates, US Venture Partners, and Versant Ventures.
The company intends to use the funds to continue to introduce the WEBTM Aneurysm Embolization System, including execution of a planned US IDE clinical study, and to broaden its product portfolio.
Founded in 2007 and led by Tom Wilder, President and Chief Executive Officer, Sequent Medical is dedicated to the development of innovative catheter-based neurovascular technologies. Its VIA® Microcatheter has received the CE mark and was cleared for commercial use in the United States; the WEB Aneurysm Embolization System WEB Aneurysm Embolization System has received the CE mark but is not approved for use in the United States.
The company has European operations based in Bonn, Germany.
FinSMEs
08/04/2014